Rhumbline Advisers Sells 11,088 Shares of Qiagen N.V. $QGEN

Rhumbline Advisers lessened its position in Qiagen N.V. (NYSE:QGEN) by 5.4% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 194,303 shares of the company’s stock after selling 11,088 shares during the period. Rhumbline Advisers owned about 0.09% of Qiagen worth $7,801,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in QGEN. Ameriprise Financial Inc. lifted its stake in shares of Qiagen by 66.3% in the fourth quarter. Ameriprise Financial Inc. now owns 63,026 shares of the company’s stock worth $2,807,000 after buying an additional 25,134 shares in the last quarter. Cetera Investment Advisers lifted its position in Qiagen by 14.4% during the fourth quarter. Cetera Investment Advisers now owns 11,297 shares of the company’s stock valued at $505,000 after purchasing an additional 1,418 shares during the period. Ensign Peak Advisors Inc bought a new position in Qiagen during the fourth quarter valued at approximately $703,000. Janus Henderson Group PLC lifted its position in Qiagen by 114.3% during the fourth quarter. Janus Henderson Group PLC now owns 270,171 shares of the company’s stock valued at $11,999,000 after purchasing an additional 144,112 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Qiagen by 3.4% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 170,957 shares of the company’s stock worth $7,613,000 after acquiring an additional 5,681 shares during the period. Institutional investors own 70.00% of the company’s stock.

Qiagen Stock Performance

Shares of NYSE:QGEN opened at $46.06 on Friday. Qiagen N.V. has a 52 week low of $37.63 and a 52 week high of $51.88. The stock has a market capitalization of $10.24 billion, a P/E ratio of 27.21, a PEG ratio of 2.43 and a beta of 0.64. The firm has a fifty day simple moving average of $48.53 and a two-hundred day simple moving average of $44.55. The company has a quick ratio of 1.35, a current ratio of 1.61 and a debt-to-equity ratio of 0.25.

Qiagen (NYSE:QGEN) last released its earnings results on Tuesday, August 5th. The company reported $0.60 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.60. The firm had revenue of $533.54 million during the quarter, compared to analyst estimates of $523.97 million. Qiagen had a net margin of 18.30% and a return on equity of 14.77%. The business’s revenue was up 7.7% on a year-over-year basis. During the same quarter last year, the business earned $0.55 EPS. Qiagen has set its Q3 2025 guidance at 0.580- EPS. FY 2025 guidance at 2.350-2.350 EPS. On average, analysts expect that Qiagen N.V. will post 2.26 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on QGEN shares. UBS Group increased their price target on shares of Qiagen from $48.00 to $50.00 and gave the stock a “neutral” rating in a research report on Thursday, August 7th. Wall Street Zen downgraded shares of Qiagen from a “strong-buy” rating to a “buy” rating in a research report on Monday, August 11th. Barclays began coverage on Qiagen in a research note on Tuesday, June 24th. They issued an “overweight” rating and a $55.00 price target for the company. Cowen restated a “hold” rating on shares of Qiagen in a research report on Thursday, August 7th. Finally, Bank of America upped their price objective on Qiagen from $50.00 to $53.00 and gave the stock a “buy” rating in a research note on Thursday, June 26th. Three investment analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $49.69.

About Qiagen

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.